{
    "clinical_study": {
        "@rank": "16762", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Cohort 4", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Optional Cohort 5", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to evaluate the safety and plasma concentrations of PF-06649751 in\n      healthy volunteers following one or two times daily oral dosing of PF-06649751 for 14 days."
        }, 
        "brief_title": "A Study To Observe Safety And Blood Concentrations Of PF-06649751 During And Following The Oral Administration Of Multiple Doses Of PF-06649751 In Healthy Adult Volunteers", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy males and/or female subjects of non childbearing potential between the ages\n             of 18 and 55 years, inclusive (healthy is defined as no clinically relevant\n             abnormalities identified by a detailed medical history, full physical examination,\n             including blood pressure and pulse rate measurement, 12 lead ECG and clinical\n             laboratory tests).\n\n          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110\n             lbs).\n\n        Exclusion Criteria:\n\n          -  Evidence or history of clinically significant hematological, renal, endocrine,\n             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or\n             allergic disease (including drug allergies, but excluding untreated, asymptomatic,\n             seasonal allergies at the time of dosing).\n\n          -  Other severe acute or chronic medical or psychiatric condition or laboratory\n             abnormality that may increase the risk associated with study participation or\n             investigational product administration or may interfere with the interpretation of\n             study results and, in the judgment of the investigator, would make the subject\n             inappropriate for entry into this study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02066909", 
            "org_study_id": "B7601002"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cohort 1", 
                "description": "Oral dosing of 0.15 mg PF-06649751 extemporaneously-prepared solution given once-daily for 14 days.", 
                "intervention_name": "0.15 mg PF-06649751", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "description": "Oral dosing of 0.5 mg PF-06649751 extemporaneously-prepared solution given once-daily for 14 days.", 
                "intervention_name": "0.5 mg PF-06649751", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "description": "Oral dosing of 1.5 mg PF-06649751 extemporaneously-prepared solution given once-daily for 14 days.", 
                "intervention_name": "1.5 mg PF-06649751", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort 4", 
                "description": "Oral dosing of 1.0 mg PF-06649751 extemporaneously-prepared solution given twice-daily for 14 days.", 
                "intervention_name": "1.0 mg PF-06649751", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Optional Cohort 5", 
                "description": "Oral dosing of PF-06649751 extemporaneously-prepared solution given twice-daily for 14 days. Dosage and frequency to-be-determined based on previous cohorts.", 
                "intervention_name": "TBD mg PF-06649751", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "pharmacokinetics", 
            "safety", 
            "tolerability", 
            "healthy volunteers", 
            "steady state", 
            "multiple doses"
        ], 
        "lastchanged_date": "May 29, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7601002&StudyName=A%20Study%20To%20Observe%20Safety%20And%20Blood%20Concentrations%20Of%20PF-06649751%20During%20And%20Following%20The%20Oral%20Administration%20Of%20Multiple%20Doses%20Of%20PF"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06511"
                }, 
                "name": "Pfizer Investigational Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo Controlled, Dose Escalation, Parallel Group Study To Investigate The Safety, Tolerability And Pharmacokinetics Of Repeat Doses Of Pf-06649751 In Healthy Subjects", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Measurement of blood pressure and pulse rate", 
                "measure": "Supine and standing vital sign measurements", 
                "safety_issue": "Yes", 
                "time_frame": "0-18 days"
            }, 
            {
                "measure": "Amount of unchanged drug excreted in urine relative to dose (Ae%)", 
                "safety_issue": "No", 
                "time_frame": "Day 14"
            }, 
            {
                "measure": "Renal Clearance (CLR)", 
                "safety_issue": "No", 
                "time_frame": "Day 14"
            }, 
            {
                "measure": "Area Under the Curve from Time Zero to end of dosing interval (AUCtau)", 
                "safety_issue": "No", 
                "time_frame": "Day 1, 7 and 14"
            }, 
            {
                "description": "Maximum plasma concentration", 
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Day 1, 7 and 14"
            }, 
            {
                "description": "Time for Cmax", 
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "Day 1, 7 and 14"
            }, 
            {
                "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.", 
                "measure": "Plasma Decay Half-Life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "14 - 18 days"
            }, 
            {
                "description": "Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.  Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling.  Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.", 
                "measure": "Apparent Oral Clearance (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "0 - 18 days"
            }, 
            {
                "description": "Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.", 
                "measure": "Apparent Volume of Distribution (Vz/F)", 
                "safety_issue": "No", 
                "time_frame": "0 - 18 days"
            }, 
            {
                "description": "Minimum concentration pre-dose", 
                "measure": "Trough Concentration (Ctrough)", 
                "safety_issue": "No", 
                "time_frame": "0 - 14 days"
            }, 
            {
                "description": "Ratio of accumulation for AUCtau", 
                "measure": "Ratio of accumulation for AUCtau (Rac AUCtau)", 
                "safety_issue": "No", 
                "time_frame": "Day 1, 7 and 14"
            }, 
            {
                "description": "Ratio of accumulation for Cmax", 
                "measure": "Ratio of accumulation for Cmax (Rac Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Day 1, 7 and 14"
            }, 
            {
                "description": "Peak-to-trough ratio at steady state", 
                "measure": "Peak-to-trough ratio (PTR)", 
                "safety_issue": "No", 
                "time_frame": "Day 7 and 14"
            }, 
            {
                "description": "C-SSRS assessed whether participant experienced following: completed suicide (1), suicide attempt (2) (response of \"Yes\" on \"actual attempt\"), preparatory acts toward imminent suicidal behavior (3)(\"Yes\" on \"preparatory acts or behavior\"), suicidal ideation (4) (\"Yes\" on \"wish to be dead\", \"non-specific active suicidal thoughts\", \"active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent), any suicidal behavior or ideation, self-injurious behavior (7)(\"Yes\" on \"Has subject engaged in non-suicidal self-injurious behavior\").", 
                "measure": "Number of Participants with categorical scores on the Columbia Suicide Severity Rating Scale (C-SSRS)", 
                "safety_issue": "Yes", 
                "time_frame": "Day 0 and 14"
            }, 
            {
                "description": "Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose. Relatedness to [study drug] was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.", 
                "measure": "Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "0 - 18 days"
            }, 
            {
                "description": "Measurement of standard 12-lead ECG, single or triplicate", 
                "measure": "Electrocardiogram (ECG)", 
                "safety_issue": "Yes", 
                "time_frame": "0 - 18 days"
            }, 
            {
                "description": "Pre-defined criteria were established for each laboratory test to define the values that would be identified as of potential clinical importance.", 
                "measure": "Number of Participants With Laboratory Test Values of Potential Clinical Importance", 
                "safety_issue": "Yes", 
                "time_frame": "0 - 18 days"
            }, 
            {
                "description": "Cognitive impairment as measured by various tests in the Cogstate battery", 
                "measure": "Cogstate", 
                "safety_issue": "Yes", 
                "time_frame": "Day 0, 1, 7 and 14"
            }, 
            {
                "measure": "Changes from baseline in total cholesterol, High Density Lipoprotein (HDL) cholesterol, Low Density Lipoprotein (LDL) cholesterol, triglycerides", 
                "time_frame": "Day 1 and 14"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02066909"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}